Sanofi Stays Bullish On Synthorx IL-2 Drug, But It’s Early Days

Drug Maker Presents Initial Phase I Data At AACR

 
• By Alaric DeArment
Cancer
Sanofi presented early data at AACR on THOR-707, the IL-2 drug it acquired when it bought Synthorx in 2019. • Source: Shutterstock

More from Anticancer

More from Therapeutic Category